查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1452935

全球真實世界證據解決方案市場 2024-2031

Global Real-World Evidence Solutions Market 2024-2031
出版日期: | 出版商: Orion Market Research | 英文 200 Pages | 商品交期: 2-3個工作天內

價格

全球現實世界證據解決方案市場預計在預測期內（2024-2031 年）將以 12.40% 的CAGR成長。市場的成長歸因於醫療保健行業不斷成長的需求，優先考慮以患者為中心的方法，旨在更快、更有效率的臨床試驗，以加速患者獲得創新治療。例如，2023 年6 月，Verana Health推出了VeraSite，基於訂閱的工具，用於識別潛在的臨床試驗地點。該工具使申辦者和 CRO 能夠快速識別具有臨床專業知識和患者群體的實踐，指導地點選擇並允許與感興趣的實踐直接聯繫。

細分市場前景

全球現實世界證據解決方案市場按組件、應用程式和最終用戶細分。根據組成部分，市場細分為服務和資料集。根據應用，市場細分為藥物開發和核准、上市後監督、市場准入報銷/涵蓋最終用戶決策以及臨床和監管決策。此外，根據最終用戶，市場細分為製藥和醫療器材公司、醫療保健提供者、醫療保健支付者等。預計製藥和醫療器材公司的子類別會佔領最終用戶細分市場的很大一部分市場佔有率。這一成長可歸因於真實世界證據（RWE）研究的重要性日益增加，這對於藥物核准、真實世界性能評估和防止召回、幫助患者利益識別、監管批准、報銷和增加使用適應症越來越重要。

腫瘤學子細分市場預計將在全球現實世界證據解決方案市場中佔據相當大的佔有率

在這些應用中，腫瘤學子細分市場預計將在全球現實世界證據解決方案市場中佔據相當大的佔有率。該細分市場的成長歸因於癌症研究和治療中數據驅動決策的日益重視，反映了更廣泛的行業趨勢。此外，市場參與者正在尋求新產品的推出來滿足對解決方案的需求。 。例如，2023 年 5 月，Flatiron Health 擴展到腫瘤學真實世界證據生成領域。其綜合現實世界證據 (RWE) 解決方案方法使合作夥伴能夠產生強大的 RWE 和見解。它使 Flatiron 成為整個產品生命週期中腫瘤學 RWD/E 開發的“一站式商店”，從而改善癌症患者的體驗。

區域展望

全球現實世界證據解決方案市場根據地理位置進一步細分，包括北美（美國和加拿大）、歐洲（英國、義大利、西班牙、德國、法國和歐洲其他地區）、亞太地區（印度、中國、日本、韓國和亞洲其他地區）以及世界其他地區（中東和非洲以及拉丁美洲）。其中，亞太地區預計將在全球市場中佔據顯著佔有率，因為該地區老年人口數量不斷增加，癌症和慢性病發病率較高，此外，對醫療器械的需求也有所增加。醫療保健服務..

北美地區預計在全球真實世界證據解決方案市場中將以顯著的複合CAGR成長

在所有地區中，北美地區預計在預測期內將以相當大的CAGR成長。區域成長歸因於高品質現實世界資料來源的不斷增加，例如穿戴式裝置、醫療保健應用程式和電子健康記錄。 。據美國國家衛生研究院 (gov.) 稱，2023 年 10 月，該出版物對利用醫療保健領域的真實世界證據 (RWE) 的全球監管環境進行了最新回顧。它評估不同地區框架、指南、資料品質、研究方法和程序指南的可用性。該審查還強調了未來發展和協調方面的差距和潛在機會，以及監管機構和衛生技術評估 (HTA) 機構在利用 RWE 方面的協調一致。

市場參與者展望

服務全球現實世界證據解決方案市場的主要公司包括 Dassault Systemes SE、IBM Corp.、Oracle、PerkinElmer Inc.、Thermo Fisher Scientific Inc. 等。市場參與者透過各種策略（包括併購、合作、合作、融資和新產品發布），為市場成長做出了巨大貢獻，以保持市場競爭力。例如，2023 年 8 月，Thermo Fisher Scientific Inc. 收購了 CorEvitas, LLC，專注於常規臨床護理中的真實證據收集和使用，這是製藥和生物技術客戶的高成長細分市場。

2023 年 12 月，BC Platforms 收購了 Medexprim，擴大了為全球生物製藥合作夥伴提供安全存取真實臨床和影像資料資產的能力。

目錄

第 1 章：報告摘要

  • 目前行業分析及成長潛力展望
  • 研究方法和工具
  • 市場區隔
    • 按細分
    • 按地區

第 2 章：市場概述與見解

  • 報告範圍
  • 分析師見解和當前市場趨勢
    • 主要發現
    • 建議
    • 結論

第 3 章：競爭格局

  • 主要公司分析
  • Cegedim Health
    • 概述
    • 財務分析
    • SWOT分析
    • 最近的發展
  • Clinigen Ltd.
    • 概述
    • 財務分析
    • SWOT分析
    • 最近的發展
  • Cognizant Technology Solutions Corp.
    • 概述
    • 財務分析
    • SWOT分析
    • 最近的發展
  • 關鍵策略分析

第 4 章：市場細分

  • 按組件分類的全球真實世界證據解決方案市場
    • 服務
    • 資料集
      • 不同的資料集
      • 綜合資料集
  • 全球真實世界證據解決方案市場（按應用）
    • 藥物開發和批准
    • 上市後監督
    • 市場准入報銷/涵蓋最終用戶決策
    • 臨床和監管決策
  • 按最終用戶分類的全球真實世界證據解決方案市場
    • 製藥及醫療器材公司
    • 醫療保健機構
    • 醫療保健支付者
    • 其他（病患和病患權益團體、研究組織和學術界）

第 5 章：區域分析

  • 北美洲
    • 美國
    • 加拿大
  • 歐洲
    • 英國
    • 德國
    • 義大利
    • 西班牙
    • 法國
    • 歐洲其他地區
  • 亞太
    • 中國
    • 印度
    • 日本
    • 韓國
    • 亞太其他地區
  • 世界其他地區

第 6 章：公司簡介

  • Dassault Systemes S.E.
  • Flatiron Health
  • IBM Corp.
  • ICON plc.
  • India Medtronic Pvt. Ltd.
  • IQVIA, Inc.
  • Optum, Inc.
  • Oracle
  • Parexel International Corp.
  • PerkinElmer Inc.
  • Real Endpoints
  • Saama Technologies, LLC.
  • SAS Institute Inc.
  • Syneos Health
  • Thermo Fisher Scientific Inc.
  • TriNetX LLC
Product Code: OMR2028128

Global Real World Evidence Solutions Market Size, Share & Trends Analysis Report by Component (Services, and Data Sets), by Application (Drug Development and Approvals, Post-Market Surveillance, Market Access Reimbursement/Cover End-User Decision Making, and Clinical and Regulatory Decision-Making), and by End-User (Pharmaceutical & Medical Device Companies, Healthcare Providers, Healthcare Payers, and Others ) Forecast Period (2024-2031)

The global real-world evidence solutions market is anticipated to grow at a CAGR of 12.40% during the forecast period (2024-2031). The market's growth is attributed to the growing demand for healthcare industry is prioritizing patient-centric approaches, aiming for faster and more efficient clinical trials to expedite access to innovative treatments for patients.. For instance, in June 2023, Verana Health launched VeraSite, a subscription-based tool for identifying potential clinical trial sites. The tool allows sponsors and CROs to quickly identify practices with clinical expertise and patient populations, guiding site selection and allowing direct contact with practices of interest.

Segmental Outlook

The global real-world evidence solutions market is segmented by component, application, and end user. Based on the component, the market is sub-segmented into services, and data sets.. Based on the application, the market is sub-segmented intodrug development and approvals, post-market surveillance, market access reimbursement/cover end-user decision making, and clinical and regulatory decision-making.. Furthermore, based on end users, the market is sub-segmented into pharmaceutical & medical device companies, healthcare providers, healthcare payers, and others.. The pharmaceutical and medical device companies' subcategory is expected to capture a significant portion of the market share within the end-user segment. The growth can be attributed to the increasing importance of real world evidence (RWE) studies are increasingly crucial in drug approval, real-world performance assessment, and preventing recalls, aiding in patient benefit identification, regulatory approvals, reimbursement, and increased indications of use.

Oncology Sub-Sub-Segment is Anticipated to Hold a Considerable Share of the Global Real-World Evidence Solutions Market

Among the applications, the oncology sub-sub-segment is expected to hold a considerable share of the global real-world evidence solutions market. The segmental growth is attributed to the growing emphasis for data-driven decision-making in cancer research and treatment, reflecting wider industry trends. Furthermore, the market players are looking for the new product launch to meet the demand for the solutions. . For instance, in May 2023, Flatiron Health expanded into oncology real-world evidence generation. Its Integrated real-world evidence (RWE) Solutions approach allows partners to generate strong RWE and insights. It enables Flatiron to become a 'one-stop-shop' for oncology RWD/E development across the product lifecycle, hence enhancing cancer patient experiences.

Regional Outlook

The global real-world evidence solutions market is further segmented based on geography including North America (the US, and Canada), Europe (UK, Italy, Spain, Germany, France, and the Rest of Europe), Asia-Pacific (India, China, Japan, South Korea, and Rest of Asia), and the Rest of the World (the Middle East & Africa, and Latin America). Among these, Asia-Pacific is anticipated to hold a prominent share of the market across the globe, owing to the growing number of elderly individuals and the higher occurrence of cancer and chronic illnesses in the region, additionally there has been an increase in demand for healthcare services..

The North American region is Expected to Grow at a Significant CAGR in the global Real-World Evidence Solutions Market

Among all regions, the North American region is anticipated to grow at a considerable CAGR over the forecast period. Regional growth is attributed to the growing availability of high-quality real-world data sources such as wearables, healthcare apps, and electronic health records. . According to the National Institute og Health (gov.), in October 2023, the publication provides an updated review of the global regulatory landscape for leveraging real-world evidence (RWE) in healthcare. It evaluates the availability of frameworks, guidance, data quality, study methods, and procedural guidance in different regions. The review also highlights gaps and potential opportunities for future development and harmonization, as well as the alignment among regulators and health technology assessment (HTA) bodies in utilizing RWE..

Market Players Outlook

The major companies serving the global real-world evidence solutions market include Dassault Systemes S.E., IBM Corp., Oracle, PerkinElmer Inc., Thermo Fisher Scientific Inc., and others. The market players are considerably contributing to the market growth by the adoption of various strategies including mergers and acquisitions, partnerships, collaborations, funding, and new product launches, to stay competitive in the market. For instance, in August 2023, Thermo Fisher Scientific Inc. acquired CorEvitas, LLC, focusing on real-world evidence collection and use in routine clinical care, a high-growth market segment for pharmaceutical and biotechnology customers.

In December 2023, BC Platforms acquired Medexprim, expanding its capability to offer global biopharma partners secure access to real-world clinical and imaging data assets.

The Report Covers:

  • Market value data analysis of 2023 and forecast to 2031.
  • Annualized market revenues ($ million) for each market segment.
  • Country-wise analysis of major geographical regions.
  • Key companies operating in the global real-world evidence solutions market. Based on the availability of data, information related to new product launches, and relevant news is also available in the report.
  • Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.
  • Analysis of market-entry and market expansion strategies. Competitive strategies by identifying 'who-stands-where' in the market.

Table of Contents

1.Report Summary

  • Current Industry Analysis and Growth Potential Outlook
  • 1.1.Research Methods and Tools
  • 1.2.Market Breakdown
    • 1.2.1.By Segments
    • 1.2.2.By Region

2.Market Overview and Insights

  • 2.1.Scope of the Report
  • 2.2.Analyst Insight & Current Market Trends
    • 2.2.1.Key Findings
    • 2.2.2.Recommendations
    • 2.2.3.Conclusion

3.Competitive Landscape

  • 3.1.Key Company Analysis
  • 3.2.Cegedim Health
    • 3.2.1.Overview
    • 3.2.2.Financial Analysis
    • 3.2.3.SWOT Analysis
    • 3.2.4.Recent Developments
  • 3.3.Clinigen Ltd.
    • 3.3.1.Overview
    • 3.3.2.Financial Analysis
    • 3.3.3.SWOT Analysis
    • 3.3.4.Recent Developments
  • 3.4.Cognizant Technology Solutions Corp.
    • 3.4.1.Overview
    • 3.4.2.Financial Analysis
    • 3.4.3.SWOT Analysis
    • 3.4.4.Recent Developments
  • 3.5.Key Strategy Analysis

4.Market Segmentation

  • 4.1.Global Real-World Evidence Solutions Market by Component
    • 4.1.1.Services
    • 4.1.2.Data Sets
      • 4.1.2.1.Disparate Data Sets
      • 4.1.2.2.Integrated Data Sets
  • 4.2.Global Real-World Evidence Solutions Market by Application
    • 4.2.1.Drug Development and Approvals
    • 4.2.2.Post-Market Surveillance
    • 4.2.3.Market Access Reimbursement/Cover End-User Decision Making
    • 4.2.4.Clinical and Regulatory Decision-Making
  • 4.3.Global Real-World Evidence Solutions Market by End-User
    • 4.3.1.Pharmaceutical & Medical Device Companies
    • 4.3.2.Healthcare Providers
    • 4.3.3.Healthcare Payers
    • 4.3.4.Others (Patients and Patient Advocacy Groups, Research Organizations and Academia)

5.Regional Analysis

  • 5.1.North America
    • 5.1.1.United States
    • 5.1.2.Canada
  • 5.2.Europe
    • 5.2.1.UK
    • 5.2.2.Germany
    • 5.2.3.Italy
    • 5.2.4.Spain
    • 5.2.5.France
    • 5.2.6.Rest of Europe
  • 5.3.Asia-Pacific
    • 5.3.1.China
    • 5.3.2.India
    • 5.3.3.Japan
    • 5.3.4.South Korea
    • 5.3.5.Rest of Asia-Pacific
  • 5.4.Rest of the World

6.Company Profiles

  • 6.1.Dassault Systemes S.E.
  • 6.2.Flatiron Health
  • 6.3.IBM Corp.
  • 6.4.ICON plc.
  • 6.5.India Medtronic Pvt. Ltd.
  • 6.6.IQVIA, Inc.
  • 6.7.Optum, Inc.
  • 6.8.Oracle
  • 6.9.Parexel International Corp.
  • 6.10.PerkinElmer Inc.
  • 6.11.Real Endpoints
  • 6.12.Saama Technologies, LLC.
  • 6.13.SAS Institute Inc.
  • 6.14.Syneos Health
  • 6.15.Thermo Fisher Scientific Inc.
  • 6.16.TriNetX LLC

LIST OF TABLES

  • 1.GLOBAL REAL-WORLD EVIDENCE SOLUTIONS MARKET RESEARCH AND ANALYSIS BY COMPONENT, 2023-2031 ($ MILLION)
  • 2.GLOBAL REAL-WORLD EVIDENCE SOLUTIONS BY SERVICES MARKET RESEARCH AND ANALYSIS BY REGION, 2023-2031 ($ MILLION)
  • 3.GLOBAL REAL-WORLD EVIDENCE SOLUTIONS BY DATA SETS MARKET RESEARCH AND ANALYSIS BY REGION, 2023-2031 ($ MILLION)
  • 4.GLOBAL REAL-WORLD EVIDENCE SOLUTIONS MARKET RESEARCH AND ANALYSIS BY APPLICATION, 2023-2031 ($ MILLION)
  • 5.GLOBAL REAL-WORLD EVIDENCE SOLUTIONS IN DRUG DEVELOPMENT AND APPROVALS MARKET RESEARCH AND ANALYSIS BY REGION, 2023-2031 ($ MILLION)
  • 6.GLOBAL REAL-WORLD EVIDENCE SOLUTIONS IN POST-MARKET SURVEILLANCE MARKET RESEARCH AND ANALYSIS BY REGION, 2023-2031 ($ MILLION)
  • 7.GLOBAL REAL-WORLD EVIDENCE SOLUTIONS IN ACCESS REIMBURSEMENT/COVER END USER DECISION MAKING MARKET RESEARCH AND ANALYSIS BY REGION, 2023-2031 ($ MILLION)
  • 8.GLOBAL REAL-WORLD EVIDENCE SOLUTIONS IN CLINICAL AND REGULATORY DECISION-MAKING MARKET RESEARCH AND ANALYSIS BY REGION, 2023-2031 ($ MILLION)
  • 9.GLOBAL REAL-WORLD EVIDENCE SOLUTIONS MARKET RESEARCH AND ANALYSIS BY END-USER, 2023-2031 ($ MILLION)
  • 10.GLOBAL REAL-WORLD EVIDENCE SOLUTIONS FOR PHARMACEUTICAL & MEDICAL DEVICE COMPANIES MARKET RESEARCH AND ANALYSIS BY REGION, 2023-2031 ($ MILLION)
  • 11.GLOBAL REAL-WORLD EVIDENCE SOLUTIONS FOR HEALTHCARE PROVIDERS MARKET RESEARCH AND ANALYSIS BY REGION, 2023-2031 ($ MILLION)
  • 12.GLOBAL REAL-WORLD EVIDENCE SOLUTIONS FOR HEALTHCARE PAYERS MARKET RESEARCH AND ANALYSIS BY REGION, 2023-2031 ($ MILLION)
  • 13.GLOBAL REAL-WORLD EVIDENCE SOLUTIONS FOR OTHER END-USERS MARKET RESEARCH AND ANALYSIS BY REGION, 2023-2031 ($ MILLION)
  • 14.GLOBAL REAL-WORLD EVIDENCE SOLUTIONS MARKET RESEARCH AND ANALYSIS BY REGION, 2023-2031 ($ MILLION)
  • 15.NORTH AMERICAN REAL-WORLD EVIDENCE SOLUTIONS MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2023-2031 ($ MILLION)
  • 16.NORTH AMERICAN REAL-WORLD EVIDENCE SOLUTIONS MARKET RESEARCH AND ANALYSIS BY COMPONENT, 2023-2031 ($ MILLION)
  • 17.NORTH AMERICAN REAL-WORLD EVIDENCE SOLUTIONS MARKET RESEARCH AND ANALYSIS BY APPLICATION, 2023-2031 ($ MILLION)
  • 18.NORTH AMERICAN REAL-WORLD EVIDENCE SOLUTIONS MARKET RESEARCH AND ANALYSIS BY END-USER, 2023-2031 ($ MILLION)
  • 19.EUROPEAN REAL-WORLD EVIDENCE SOLUTIONS MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2023-2031 ($ MILLION)
  • 20.EUROPEAN REAL-WORLD EVIDENCE SOLUTIONS MARKET RESEARCH AND ANALYSIS BY COMPONENT, 2023-2031 ($ MILLION)
  • 21.EUROPEAN REAL-WORLD EVIDENCE SOLUTIONS MARKET RESEARCH AND ANALYSIS BY APPLICATION, 2023-2031 ($ MILLION)
  • 22.EUROPEAN REAL-WORLD EVIDENCE SOLUTIONS MARKET RESEARCH AND ANALYSIS BY END-USER, 2023-2031 ($ MILLION)
  • 23.ASIA-PACIFIC REAL-WORLD EVIDENCE SOLUTIONS MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2023-2031 ($ MILLION)
  • 24.ASIA-PACIFIC REAL-WORLD EVIDENCE SOLUTIONS MARKET RESEARCH AND ANALYSIS BY COMPONENT, 2023-2031 ($ MILLION)
  • 25.ASIA-PACIFIC REAL-WORLD EVIDENCE SOLUTIONS MARKET RESEARCH AND ANALYSIS BY APPLICATION, 2023-2031 ($ MILLION)
  • 26.ASIA-PACIFIC REAL-WORLD EVIDENCE SOLUTIONS MARKET RESEARCH AND ANALYSIS BY END-USER, 2023-2031 ($ MILLION)
  • 27.REST OF THE WORLD REAL-WORLD EVIDENCE SOLUTIONS MARKET RESEARCH AND ANALYSIS BY REGION, 2023-2031 ($ MILLION)
  • 28.REST OF THE WORLD REAL-WORLD EVIDENCE SOLUTIONS MARKET RESEARCH AND ANALYSIS BY COMPONENT, 2023-2031 ($ MILLION)
  • 29.REST OF THE WORLD REAL-WORLD EVIDENCE SOLUTIONS MARKET RESEARCH AND ANALYSIS BY APPLICATION, 2023-2031 ($ MILLION)
  • 30.REST OF THE WORLD REAL-WORLD EVIDENCE SOLUTIONS MARKET RESEARCH AND ANALYSIS BY END USER, 2023-2031 ($ MILLION)

LIST OF FIGURES

  • 1.GLOBAL REAL-WORLD EVIDENCE SOLUTIONS MARKET SHARE BY COMPONENT, 2023 VS 2031 (%)
  • 2.GLOBAL REAL-WORLD EVIDENCE SOLUTIONS BY SERVICES MARKET SHARE BY REGION, 2023 VS 2031 (%)
  • 3.GLOBAL REAL-WORLD EVIDENCE SOLUTIONS BY DATA SETS MARKET SHARE BY REGION, 2023 VS 2031 (%)
  • 4.GLOBAL REAL-WORLD EVIDENCE SOLUTIONS BY DISPARATE DATA SETS MARKET SHARE BY REGION, 2023 VS 2031 (%)
  • 5.GLOBAL REAL-WORLD EVIDENCE SOLUTIONS BY INTEGRATED DATA SETS MARKET SHARE BY REGION, 2023 VS 2031 (%)
  • 6.GLOBAL REAL-WORLD EVIDENCE SOLUTIONS MARKET SHARE BY APPLICATION, 2023 VS 2031 (%)
  • 7.GLOBAL REAL-WORLD EVIDENCE SOLUTIONS IN DRUG DEVELOPMENT AND APPROVALS MARKET SHARE BY REGION, 2023 VS 2031 (%)
  • 8.GLOBAL REAL-WORLD EVIDENCE SOLUTIONS IN ONCOLOGY MARKET SHARE BY REGION, 2023 VS 2031 (%)
  • 9.GLOBAL REAL-WORLD EVIDENCE SOLUTIONS IN NEUROLOGY MARKET SHARE BY REGION, 2023 VS 2031 (%)
  • 10.GLOBAL REAL-WORLD EVIDENCE SOLUTIONS IN IMMUNOLOGY MARKET SHARE BY REGION, 2023 VS 2031 (%)
  • 11.GLOBAL REAL-WORLD EVIDENCE SOLUTIONS IN CARDIOVASCULAR DISEASE MARKET SHARE BY REGION, 2023 VS 2031 (%)
  • 12.GLOBAL REAL-WORLD EVIDENCE SOLUTIONS IN OTHER THERAPEUTIC AREAS MARKET SHARE BY REGION, 2023 VS 2031 (%)
  • 13.GLOBAL REAL-WORLD EVIDENCE SOLUTIONS IN MEDICAL DEVICE DEVELOPMENT AND APPROVALS MARKET SHARE BY REGION, 2023 VS 2031 (%)
  • 14.GLOBAL REAL-WORLD EVIDENCE SOLUTIONS IN POST-MARKET SURVEILLANCE MARKET SHARE BY REGION, 2023 VS 2031 (%)
  • 15.GLOBAL REAL-WORLD EVIDENCE SOLUTIONS IN MARKET ACCESS REIMBURSEMENT/COVERAGE DECISION MAKING MARKET SHARE BY REGION, 2023 VS 2031 (%)
  • 16.GLOBAL REAL-WORLD EVIDENCE SOLUTIONS IN CLINICAL AND REGULATORY DECISION-MAKING MARKET SHARE BY REGION, 2023 VS 2031 (%)
  • 17. GLOBAL REAL-WORLD EVIDENCE SOLUTIONS MARKET SHARE BY END-USER, 2023 VS 2031 (%)
  • 18.GLOBAL REAL-WORLD EVIDENCE SOLUTIONS FOR PHARMACEUTICAL & MEDICAL DEVICE COMPANIES MARKET SHARE BY REGION, 2023 VS 2031 (%)
  • 19.GLOBAL REAL-WORLD EVIDENCE SOLUTIONS FOR HEALTHCARE PROVIDERS MARKET SHARE BY REGION, 2023 VS 2031 (%)
  • 20.GLOBAL REAL-WORLD EVIDENCE SOLUTIONS FOR HEALTHCARE PAYERS MARKET SHARE BY REGION, 2023 VS 2031 (%)
  • 21.GLOBAL REAL-WORLD EVIDENCE SOLUTIONS FOR OTHERS MARKET SHARE BY REGION, 2023 VS 2031 (%)
  • 22.GLOBAL REAL-WORLD EVIDENCE SOLUTIONS MARKET SHARE BY REGION, 2023 VS 2031 (%)
  • 23.US REAL-WORLD EVIDENCE SOLUTIONS MARKET SIZE, 2023-2031 ($ MILLION)
  • 24.CANADA REAL-WORLD EVIDENCE SOLUTIONS MARKET SIZE, 2023-2031 ($ MILLION)
  • 25.UK REAL-WORLD EVIDENCE SOLUTIONS MARKET SIZE, 2023-2031 ($ MILLION)
  • 26.FRANCE REAL-WORLD EVIDENCE SOLUTIONS MARKET SIZE, 2023-2031 ($ MILLION)
  • 27.GERMANY REAL-WORLD EVIDENCE SOLUTIONS MARKET SIZE, 2023-2031 ($ MILLION)
  • 28.ITALY REAL-WORLD EVIDENCE SOLUTIONS MARKET SIZE, 2023-2031 ($ MILLION)
  • 29.SPAIN REAL-WORLD EVIDENCE SOLUTIONS MARKET SIZE, 2023-2031 ($ MILLION)
  • 30.REST OF EUROPE REAL-WORLD EVIDENCE SOLUTIONS MARKET SIZE, 2023-2031 ($ MILLION)
  • 31.INDIA REAL-WORLD EVIDENCE SOLUTIONS MARKET SIZE, 2023-2031 ($ MILLION)
  • 32.CHINA REAL-WORLD EVIDENCE SOLUTIONS MARKET SIZE, 2023-2031 ($ MILLION)
  • 33.JAPAN REAL-WORLD EVIDENCE SOLUTIONS MARKET SIZE, 2023-2031 ($ MILLION)
  • 34.SOUTH KOREA REAL-WORLD EVIDENCE SOLUTIONS MARKET SIZE, 2023-2031 ($ MILLION)
  • 35.REST OF ASIA-PACIFIC REAL-WORLD EVIDENCE SOLUTIONS MARKET SIZE, 2023-2031 ($ MILLION)
  • 36.LATIN AMERICA REAL-WORLD EVIDENCE SOLUTIONS MARKET SIZE, 2023-2031 ($ MILLION)
  • 37.THE MIDDLE EAST & AFRICA REAL-WORLD EVIDENCE SOLUTIONS MARKET SIZE, 2023-2031 ($ MILLION)